Objectives This study sought to evaluate the impact of sex differences on fractional flow reserve (FFR)-guided percutaneous coronary intervention (PCI).
Historically, women have higher in-hospital mortality rates and are at increased risk for adverse outcomes than men are after percutaneous coronary intervention (PCI) for coronary artery disease (CAD) (1, 2) . Improvements in treatment modalities, however, have narrowed these sex-associated differences, with recent studies showing similar outcomes after PCI in women and men (3) (4) (5) . Nevertheless, women are less likely to undergo invasive treatment than are men (6) and are less frequently enrolled in clinical studies evaluating coronary revascularization strategies (7) .
Fractional flow reserve (FFR) is a validated method for obtaining reliable functional information of a coronary stenosis. The FAME (Fractional Flow Reserve Versus Angiography for Multivessel Evaluation) study demonstrated that FFR-guided PCI improves outcomes and saves money compared with an angiography-guided strategy in patients with multivessel CAD (8 -10) . However, it is unknown whether the functional significance of coronary lesions is different between women and men. Moreover, the role of FFR-guided PCI in women versus men has not been evaluated. In the current study, we performed a post hoc subanalysis of the data from the FAME study to evaluate the impact of sex differences on FFR and the benefits of FFR-guided PCI.
Methods
Studydesignandpopulation. This study was a sex-specific analysis of the 2-year results of the FAME study (10) . Details regarding the design, methods, and endpoints of this prospective, multicenter, randomized clinical trial have been reported (8) . In brief, 1,005 patients with multivessel CAD were randomly assigned to either angiography-or FFRguided PCI. All patients had coronary lesions of Ն50% diameter stenosis in Ն2 major epicardial vessels, which, based on the angiographic appearance and clinical data, were felt to require PCI. Patients randomized to angiography-guided PCI underwent stenting of all indicated lesions with drug-eluting stents (DES). In patients assigned to FFR-guided PCI, FFR was measured in each diseased coronary artery and stents were placed only if the FFR was Յ0.80. Patients were excluded if they had left main CAD, prior coronary artery bypass graft surgery, a recent ST-segment elevation myocardial infarction (Ͻ5 days), cardiogenic shock, or extremely tortuous or calcified coronary arteries. The study protocol was approved by each Institutional Review Board or Ethics Committee, and each patient provided written informed consent. Procedure and adjunctive therapy. PCI was performed according to standard coronary interventional techniques with DES, with the final interventional strategy left to the discretion of the treating physician. FFR was measured with a coronary pressure guidewire (St. Jude Medical Systems, Uppsala, Sweden) at maximum hyperemia induced by intravenous adenosine, and hyperemic pressure pullback recordings were performed as necessary (8, 11) . FFR was defined as the ratio between the mean distal coronary pressure and the mean aortic pressure. All patients received dual antiplatelet therapy with aspirin and clopidogrel for at least 1 year after PCI. Endpoint. All adverse clinical events were centrally adjudicated by an independent Clinical Events Committee blinded to treatment. The primary interest of this reanalysis was the occurrence of major adverse cardiac events (MACE), a composite of all-cause death, myocardial infarction (MI), or need for repeat coronary revascularization, at 2 years after PCI in each sex. Secondary endpoints included the individual components of MACE. Details on these definitions have been described (8, 10) . Another main goal of this analysis was to compare FFR values between women and men with similar degrees of CAD by visual estimation. Statistical analysis. Statistical comparisons based on sex were stratified by treatment method. Continuous variables are presented as mean Ϯ SD, and categorical variables as numbers or percentages. Between-group differences in categorical variables were assessed using the chi-square test or Fisher exact test, as appropriate, and differences in continuous variables were assessed using Student t test. Analyses investigating the interaction between sex and treatment method were also performed using Breslow-Day test. Angiographic lesion severity per category and the respective FFR value of each specific lesion were plotted using a box-and-whisker plot. Survival curves were constructed using the Kaplan-Meier method and compared with the log-rank test. Patients were censored at 2 years (730 days) or when events occurred. Two-tailed p values Ͻ0.05 were considered statistically significant. All statistical analysis was performed using commercially available software (SPSS version 17 for Windows, SPSS Inc., Chicago, Illinois).
Results
Baseline characteristics and procedural results. Of the 1,005 patients included in the analysis, 744 (74%) were men and 261 (26%) were women. Baseline clinical, angiographic, and procedural characteristics according to sex and treatment method are presented in Tables 1 and 2 . Compared with men, women were significantly older (68.3 Ϯ 9.5 years vs. 63.1 Ϯ 10.2 years, p Ͻ 0.001), had higher rates of hypertension (72.0% vs. 60.6%, p ϭ 0.001), and had higher rates of unstable angina presentation (39.1% vs. 30.4%, p ϭ 0.010). Vessel diameters were significantly smaller in women than in men (2.41 Ϯ 0.62 mm vs. 2.51 Ϯ 0.63 mm, p ϭ 0.002). Although women had significantly fewer lesions identified for stenting (2.6 Ϯ 0.9 vs. 2.8 Ϯ 0.9, p ϭ 0.012) The clinical and angiographic characteristics were well matched between those randomized to FFR-guided PCI and to angiography-guided PCI, in the population as a whole and based on sex. The procedure times required for FFR-and angiography-guided treatment were similar in both men and women. However, the volume of contrast agent (for men: 283 Ϯ 137 ml vs. 306 Ϯ 131 ml, p ϭ 0.019; for women: 241 Ϯ 115 ml vs. 293 Ϯ 117 ml, p Ͻ 0.001), the number of DES (for men: 2.0 Ϯ 1.2 vs. 2.8 Ϯ 1.1, p Ͻ 0.001; for women: 1.6 Ϯ 1.4 vs. 2.9 Ϯ 1.2, p Ͻ 0.001), and the total stent length (for men: 40.0 Ϯ 27.7 mm vs. 51.6 Ϯ 25.4 mm, p Ͻ 0.001; for women: 31.7 Ϯ 27.4 mm vs. 52.6 Ϯ 22.3 mm, p Ͻ 0.001) were significantly lower for each sex in patients who underwent FFR-guided therapy compared with those who underwent angiography-guided therapy. Sex differences in clinical outcomes at 2 years. Sex-specific clinical outcomes at 2-year follow-up are presented in Table 3 . Men and women had similar rates of MACE (20.2% vs. 20.3%, p ϭ 0.923), death (3.4% vs. 2.7%, p ϭ 0.591), MI (8.1% vs. 7.7%, p ϭ 0.837), and repeat revascularization (11.4% vs. 12.3%, p ϭ 0.717). The event rates were not different between men and women irrespective of the treatment method. Two-year MACE-free survival rates were also Similarly, there were no significant sex-related differences in death-, MI-, and repeat revascularization-free survival. After adjustment for differences in baseline risk factors, 2-year MACE-free survivals were not different between men and women irrespective of the treatment method. FFR values according to angiographic stenosis severity. In the FFR-guided group, a total of 1,414 lesions were noted in 509 patients. Of these, the FFR was measured successfully in 1,329 lesions (1,028 in men and 301 in women) (11) . The lesions were categorized into 50% to 70%, 71% to 90%, and 91% to 99% diameter stenosis by visual estimation. Angiographic lesion severity per category and its respective FFR values are presented in Figure 1 . FFR values were significantly higher in women than in men (0.75 Ϯ 0.18 vs. 0.71 Ϯ 0.17, p ϭ 0.001). The proportion of functionally significant lesions (FFR Յ0.80) was lower in women than in men for lesions with 50% to 70% stenosis (21.1% vs. 39.5%, p Ͻ 0.001) and for lesions with 70% to 90% stenosis (71.9% vs. 82.0%, p ϭ 0.019). In the 91% to 99% category, the proportion of patients Values are mean Ϯ SD or n (%).
LAD ϭ left anterior descending artery; SYNTAX ϭ Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery; other abbreviations as in Table 1 . Values are n (%).
MACE ϭ major adverse cardiac events; other abbreviations as in Table 1 . Similarly, the proportion of functionally significant lesions was significantly lower in women than in men with stenosis in the 50% to 90% range measured by quantitative coronary analysis: for 50% to 70% stenosis (54.5% vs. 65.2%, p ϭ 0.032) and for 70% to 90% stenosis (77.6% vs. 89.6%, p ϭ 0.017). Risk reduction with FFR-guidance. During the 2-year follow-up, MACE occurred in 17.4% in the FFR-guided group and in 22.8% in the angiography-guided group for men and in 19.2% and in 21.3%, respectively, for women. The death, MI, and repeat revascularization rates were 2.6%, 6.0%, and 10.4%, respectively, in FFR-guided group versus 4.2%, 10.3%, and 12.5%, respectively, in angiography-guided group for men and 2.4%, 6.4%, and 11.2% versus 2.9%, 8.8%, and 13.2% for women. The 2-year survivals free from MACE are depicted in Figure 2 .
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S
The relative risk reductions for death, MI, and repeat revascularization of FFR relative to angiography-guided treatment were 37%, 42%, and 17%, respectively, in men and 18%, 27%, and 15%, respectively, in women. Treatment method-by-sex interaction tests were not statistically significant for any of the outcome variables (p Ͼ 0.05).
Discussion
The 3 main findings of this study are: 1) the proportion of functionally significant lesions (FFR Յ0.80) is lower in women than in men with coronary stenoses between 50% and 90% narrowed; 2) an FFR-guided PCI strategy is equally beneficial in women as it is in men; and 3) although women in this study were older and tended to have higher rates of baseline comorbidities, their 2-year rates of cardiac events are similar to those in men irrespective of treatment strategy (FFR-or angiography-guided therapy).
FFR, a lesion-specific index, is superior to noninvasive modalities for assessing the ischemic propensity of individual coronary lesions (12) . Although it has been increasingly used to guide clinical decision making in several patient and lesion subsets (8, (13) (14) (15) , the differences in FFR results in women and men have not been previously evaluated. We demonstrated significantly higher FFR values in women than in men, despite a similar degree of angiographic stenosis and minimal luminal diameter. The proportion of functionally significant lesions (FFR Յ0.80) was significantly lower in women than in men for lesions with 50% to 90% stenosis, which suggests that lesions of similar angiographic severity are less likely to be ischemia-producing in women.
Higher FFR for similar angiographic stenosis in women may be a chance finding. However, a potential explanation for this finding is that in this study and others, women were older and more likely to have hypertension and left ventricular hypertrophy. One would expect them to have a greater degree of diastolic dysfunction, although this was not specifically studied. These abnormalities could result in microvascular dysfunction (16) , less hyperemia, and lower peak flow across any given stenosis, manifesting as a higher FFR. It could also possibly be explained by the fact that because women generally have smaller myocardial mass (17), a smaller myocardial perfusion territory will be subtended by a stenosed vessel (18) and the flow across any given stenosis may be less (19) , thereby requiring a more severe stenosis to be functionally significant. The higher FFR values in women in this study might also be due to the visual estimation of stenosis severity, which has been previously shown to be more variable and inaccurate in women, presumably due to vessel size (20, 21) .
We found no interaction between sex and the benefits of FFR-guided PCI over angiography-guided PCI on 2-year rates of MACE. As this was a post-hoc subset analysis and the number of patients in each subgroup was below the statistical power needed for significance, caution is required N T I O N S , V O L . 5 , N O . 1 0 , 2 0 1 2 in interpreting these results. However, there was no heterogeneity in benefit of FFR guidance among the subgroups for any of the outcome variables (p values were all Ͼ0.05). Our study suggests that FFR-guided therapy is superior to angiography-guided therapy in reducing adverse clinical events after multivessel PCI, regardless of sex.
J A C C : C A R D I O V A S C U L A R I N T E R V E
The final finding in this study is that the results of PCI in women, whether guided by FFR or angiography were equivalent to those in men. Older studies have shown that women have worse outcomes compared with men undergoing PCI (1,2). More contemporary studies incorporating modern medical therapy and use of DES have shown no difference in outcomes between sex (3-5). The results of the current study, which incorporates modern medical therapy and DES, found similar 2-year rates of cardiac events in men and women. Study limitations. The main limitations of this study include that it was a post hoc subanalysis of patients in the FAME study and therefore the findings should only be hypothesis generating. Because a relatively small number of women were included, the subanalysis is underpowered to determine whether FFR-guided therapy is superior to angiographyguided therapy in women with multivessel disease. Although caution is required in generalizing our findings to all patients with multivessel disease, this study was the first, to our knowledge, to evaluate the effect of sex differences on FFRguided therapy for multivessel coronary intervention.
Conclusions
The clinical implications of this study are important. Because women appear to have higher FFR values for a given stenosis, it may be even more relevant to measure FFR in women to confirm hemodynamic significance before performing PCI.
In conclusion, angiographic lesions of similar severity are less likely to be ischemia-producing in women as compared to men and an FFR-guided PCI strategy in patients with multivessel disease is equally beneficial in women as it is in men.
